文章摘要

金属硫蛋白1X 在非小细胞肺癌中的表达及临床意义

作者: 1刘春玲, 2张迪, 3吕春秀, 4杨光华, 5韩晓晨
1 唐山市人民医院病理科，河北 唐山 063000
2 华北理工大学附属医院药剂科，河北 唐山 063000 063000
3 华北理工大学附属医院血液内科，河北 唐山 063000
4 华北理工大学附属医院普外科，河北 唐山 063000
5 唐山市人民医院头颈外科，河北 唐山 063000
通讯: 韩晓晨 Email: rmyy_hxc@163.com
DOI: 10.3978/j.issn.2095-6959.2018.06.008

摘要

目的：探讨金属硫蛋白1X(metallothionein 1X，MT1X)在非小细胞肺癌(non-small cell lung cancer， NSCLC)患者的癌组织与癌旁组织中表达及临床意义，分析MT1X与NSCLC预后的相关性。 方法：纳入68例肺癌患者，采用实时定量PCR(RT-PCR)法及免疫组织化学(IHC)方法检测NSCLC患者癌与癌旁组织中MT1X mRNA及蛋白的表达情况。利用网上数据库(http://kmplot.com/analysis/)分析MT1X与NSCLC患者生存的相关性。结果：RT-PCR结果显示MT1X mRNA在癌组织中的相对表达量明显高于癌旁组织，差异有统计学意义(0.057±0.013 vs 0.011±0.008，P<0.01)；免疫组织化学结果显示MT1X在NSCLC中的阳性表达率为67.6%(46/68)，明显高于癌旁组织的39.7%(27/68)。MT1X表达水平在NSCLC患者的不同pTNM分期、分化、有无脉管侵袭、有无淋巴结转移间存在显著差异，而与患者的性别、年龄、肿瘤大小、组织学类型、肿瘤位置无关。Kaplan-Meier生存分析结果显示MT1X高表达与NSCLC患者总生存期短显著相关(P<0.001)。结论：MT1X在NSCLC患者中阳性表达与患者术后生存期短显著相关，可作为评估NSCLC患者预后的重要标志分子。
关键词： 非小细胞肺癌；金属硫蛋白1X；临床病理参数；预后

Expression of metallothionein 1X in non-small cell lung cancer and its significances

Authors: 1LIU Chunling, 2ZHANG Di, 3LÜ Chunxiu, 4YANG Guanghua, 5HAN Xiaochen
1 Department of Pathology, Tangshan People’s Hospital, Tangshan Hebei 063000, China
2 Department of Pharmacy, Affiliated Hospital of North China University of Science and Technology, Tangshan Hebei 063000, China
3 Department of Hematology, Affiliated Hospital of North China University of Science and Technology, Tangshan Hebei 063000, China
4 Department of General Surgery, Affiliated Hospital of North China University of Science and Technology, Tangshan Hebei 063000, China
5 Department of Head and Neck Surgery, Tangshan People’s hospital, Tangshan Hebei 063000, China

CorrespondingAuthor: HAN Xiaochen Email: rmyy_hxc@163.com

DOI: 10.3978/j.issn.2095-6959.2018.06.008

Abstract

Objective: To investigate the expression of metallothionein 1X (MT1X) in human non-small cell lung cancer (NSCLC), and its correlation with clinical significance as well as prognosis. Methods: A total of 68 patients with NSCLC were enrolled, the expression of MT1X mRNA and protein in tumor tissue and adjacent normal tissue were detected by real-time PCR and immunohistochemistry (IHC). The relationship between MT1X expression and clinicopathological features were statistically analyzed. Kaplan-Meier survival analysis for the relationship between survival time and MT1X signature in NSCLC was done with an online tool (http://kmplot.com/analysis/). Results: The mRNA expression of MT1X in NSCLC was 0.057±0.013, which was higher than that in adjacent normal tissues (0.011±0.008, P<0.01). The expression of MT1X protein in NSCLC was also higher than that in adjacent tissues (67.6% vs 39.7%, P<0.01). In addition, MT1X expression had significant difference in pTNM, lymph node metastasis and poor survival time, but it did not show related with age, gender, histology, tumor size and the location of tumors. Conclusion: MT1X is frequently upregulation in NSCLC, and its overexpression is significantly correlated with poor prognostic, suggesting that MT1X could be used as a potential therapeutic target for the prevention and treatment of NSCLC.
Keywords： non-small cell lung cancer; metallothionein 1X; clinicopathological factors; prognosis

文章选项

下载引文

分享